Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ornithine oxoglutarate (OKG) is a salt formed by the combination of two molecules of L-ornithine and one molecule of alpha-ketoglutarate. It functions as an anaplerotic agent and nutritional supplement, primarily investigated for its ability to replenish intermediates of the citric acid (Krebs) cycle and support the urea cycle. In metabolic disorders such as propionic acidemia, OKG acts as a precursor to alpha-ketoglutarate, helping to bypass metabolic blocks, reduce hyperammonemia, and spare endogenous glutamine. Beyond its investigational use in rare metabolic diseases, OKG has been utilized to improve nutritional status and promote recovery in burn patients and children receiving total parenteral nutrition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ornithine oxoglutarate.